Optimizing triptan safety in emergency settings under cardiovascular risk uncertainty

Detalles Bibliográficos
Autor principal:	Yalcin Golcuk
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Headache: The Journal of Head and Face Pain
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Response to “Optimizing triptan safety in emergency settings under cardiovascular risk uncertainty”
por: Ido Peles, et al.
Publicado: (2025)

Cardiovascular risk and triptan usage among patients with migraine
por: Ido Peles, et al.
Publicado: (2025)

Arterial hypertension: A safety risk of calcitonin gene‐related peptide ligand and receptor blocker class
por: David Croteau, et al.
Publicado: (2026)

The effectiveness of parenteral agents for pain reduction in patients with migraine presenting to emergency settings: A systematic review and network analysis
por: Scott W. Kirkland, et al.
Publicado: (2024)

Incidence and outcome of sudden severe headache in the emergency department
por: Ane Skaare Sjulstad, et al.
Publicado: (2025)

Association between wildfire smoke exposure and pediatric emergency department visits for headache
por: Hannah F. J. Shapiro, et al.
Publicado: (2025)

Imaging and physiology across the high–low cerebrospinal fluid pressure spectrum: Navigating diagnostic uncertainty in headache practice
por: Andrew L. Callen, et al.
Publicado: (2026)

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study
por: María Clara García‐Castillo, et al.
Publicado: (2026)

The safety and efficacy of onabotulinumtoxinA injections for children and adolescents with chronic migraine: A systematic review and meta‐analysis
por: Rebecca Lindsay, et al.
Publicado: (2024)

Driving evidence to practice for management of migraine in the emergency department: A systematic approach to guideline implementation
por: Jennifer Robblee, et al.
Publicado: (2026)

A 52‐week open‐label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine
por: David Kudrow, et al.
Publicado: (2025)

Efficacy and safety of rimegepant for the acute treatment of migraine in Japan: A dose‐ranging, double‐blind, randomized controlled trial
por: Koichi Ikeda, et al.
Publicado: (2025)

The safety and feasibility of transcranial direct current stimulation and exercise therapy for the treatment of cervicogenic headaches: A randomized pilot trial
por: Kaiden Jobin, et al.
Publicado: (2025)

Randomized controlled trial of intravenous dexamethasone to prevent relapse in the treatment of migraine in a pediatric emergency department
por: Geneviève Tourigny‐Ruel, et al.
Publicado: (2026)

Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double‐dummy pilot trial
por: Serena Laura Orr, et al.
Publicado: (2024)

Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders—A retrospective tolerability and safety study
por: Christopher C. Anderson, et al.
Publicado: (2024)

2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
por: Jennifer Robblee, et al.
Publicado: (2025)

The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies
por: Jennifer Robblee, et al.
Publicado: (2024)

Genetically proxied liability to migraine and risk of intracranial aneurysm and subarachnoid hemorrhage
por: Iyas Daghlas, et al.
Publicado: (2024)

Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: A United States claims database‐based observational cohort study
por: David W. Dodick, et al.
Publicado: (2025)

Retrofitted adult interventions aren't good enough: Why children and adolescents deserve tailored evidence‐based care for migraine in the emergency department
por: Serena L. Orr
Publicado: (2026)

From adolescence to adulthood: The role of dietary quality in headache and temporomandibular disorder risks
por: Daniela A. Godoi Gonçalves
Publicado: (2025)

Heightened migraine risk in patients with rheumatoid arthritis: A national retrospective cohort study
por: Seonyoung Kang, et al.
Publicado: (2024)

A phase 1, multicenter, open‐label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine
por: Chay Ngee Lim, et al.
Publicado: (2025)

Efficacy and safety of rimegepant for the acute treatment of migraine in Black or African American adults: A post hoc pooled subgroup analysis from three randomized, placebo‐controlled clinical trials
por: Larry Charleston, et al.
Publicado: (2026)

Plain Language Summary Publication: The 2023 protocol for update to acute treatment of adults with migraine in the emergency department: The American headache society evidence assessment of parenteral pharmacotherapies
por: Jennifer Robblee, et al.
Publicado: (2024)

Cognitive and emotional mechanisms underlying migraine quality of life
por: Shiri Shinan‐Altman, et al.
Publicado: (2026)

Rates and risk factors for migraine progression using multiple definitions of progression: Results of the longitudinal OVERCOME ( US ) study
por: Dawn C. Buse, et al.
Publicado: (2025)

Epidemiology of new daily persistent headache: A systematic review and meta‐analysis with comparison in regard to different age groups, sex, and patient sample settings
por: Maksymilian Osiowski, et al.
Publicado: (2025)

A randomized, open‐label, 5‐period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults
por: Richard B. Lipton, et al.
Publicado: (2024)

Low pulse pressure and high serum complement C1q are risk factors for hemodialysis headache: A case–control study
por: Quan Gan, et al.
Publicado: (2024)

Is poor dietary quality in adolescence a risk factor for painful temporomandibular disorders and headaches in young adulthood? A prospective study in the Danish National Birth Cohort
por: Mojdeh Mansoori, et al.
Publicado: (2025)

Higher artificial intelligence‐ ECG atrial fibrillation prediction model output and estimated physiologic aging predict higher risk of adverse vascular events in patients with migraine
por: Ping‐Hao Yang, et al.
Publicado: (2026)

Identifying cognitive‐affective mechanisms underlying disability in episodic migraine: Using the fear avoidance model to examine interactions
por: Janosch Fox, et al.
Publicado: (2025)

Sex‐specific differences in the relationship between AHA Life's Essential 8 factors and migraine disorders: A cross‐sectional evaluation in ELSA ‐Brasil study
por: Arão Belitardo de Oliveira, et al.
Publicado: (2025)

Case report: Treatment of temporomandibular joint disorder pain with V3 nerve block procedure
por: Dean Zeldich, et al.
Publicado: (2025)

Efficacy of an educational website on headaches in schoolchildren: A cluster‐randomized controlled trial
por: Henrike Goldstein, et al.
Publicado: (2025)

Phenotype of midfacial pain in 12 new cases—A multidisciplinary idiopathic facial pain syndrome
por: Marcin Straburzyński, et al.
Publicado: (2025)

Ramadan fasting in smokers with primary headache disorders: Impact of nicotine dependence on headache frequency and severity
por: Rehab Magdy, et al.
Publicado: (2025)

Sex influences the progression of cephalic mechanical and light hypersensitivities in a mouse model of chronic migraine
por: Marie Raquin, et al.
Publicado: (2025)

Ejemplares similares

Ejemplares similares